OncoMatch/Clinical Trials/NCT04874038
Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
Is NCT04874038 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Lidocaine 20mg/ml for post-mastectomy pain syndrome.
Treatment: Lidocaine 20mg/ml — Phase III, international multicentre, parallel group, blinded, 1:1 randomized controlled trial to determine the effect of an intraoperative intravenous lidocaine infusion on reducing the development of persistent pain 3-months after breast cancer surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: BRCA1 any tested
including prophylactic surgery (e.g., family history or BRCA gene mutation)
Allowed: BRCA2 any tested
including prophylactic surgery (e.g., family history or BRCA gene mutation)
Prior therapy
Cannot have received: breast surgery
Previous breast surgery within 6 months of index surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify